Science
Remdesivir is more effective for COVID-19 than standard treatment – The Times Hub
Investing.com – A study by biotech company Gilead Sciences Inc (NASDAQ: GILD) found that a short, 5-day course of treatment of moderately severe hospitalized patients
Investing.com – A study by biotech company Gilead Sciences Inc (NASDAQ: GILD) found that a short, 5-day course of treatment of moderately severe hospitalized patients with COVID-19 with experimental remdesivir was more effective than 10 days and than standard treatment, writes Market Watch.
The results of the third phase of the open-label studies were published in the American scientific journal of the medical association JAMA. The company has already received permission for emergency use of …
Continue Reading
